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ciation for Thoracic Surgerydoi:10.1016/j.jtcvs.2005.09.022Objective: Reoperations on aortic valves are associated with increased mortality,
which may affect valve prosthesis selection at the time of initial aortic valve
replacement. We analyzed our experience to determine whether reoperation itself
independently predicts mortality during aortic valve surgery.
Methods: Demographic, intraoperative, and outcome data were collected prospec-
tively on patients undergoing primary or redo aortic valve replacement or Bentall
procedures after previous aortic valve replacement with or without concomitant
coronary bypass grafting at a single institution from 1990 through 2002. Logistic
regression analyses validated by means of bootstrap methodology identified the
predictors of hospital mortality and the independent effect of reoperation.
Results: Of 2673 patients undergoing aortic valve surgery, 2375 were primary
operations, 216 were reoperations, and 82 were Bentall–after–aortic valve replace-
ment procedures. Of 298 reoperations, 32 were third and 5 were fourth procedures.
Mortality was 2.3% for primary operations, 4.6% for redo aortic valve replacement,
and 2.4% for Bentall–after–aortic valve replacement procedures. Most patients
underwent elective procedures, with mortalities of 1.6%, 1.7%, and 2.5%, respec-
tively. Hospital mortality was independently predicted by peripheral vascular dis-
ease (odds ratio, 3.6), active endocarditis (odds ratio, 2.9), worsening New York
Heart Association class (odds ratio, 2.3), and need for annular enlargement (odds
ratio, 2.1). Reoperation itself did not predict hospital mortality.
Conclusions: The risk of mortality during aortic valve surgery is due mostly to
active endocarditis, New York Heart Association class, and comorbidity. We failed
to find a significant effect of reoperation on perioperative mortality. Mechanical
valves, with their attendant anticoagulation-related morbidity, should not be im-
planted solely because of anticipated high mortality associated with bioprosthetic
rereplacement.
Reoperative aortic valve surgery has traditionally been associated with sig-nificant mortality and morbidity.1 Mechanical valves have a long record ofexcellent durability2 but significant morbidity and sometimes mortality
related to anticoagulant-related hemorrhage and other factors.3-5 Bioprosthetic aor-
tic valves have excellent freedom from thromboembolism3,4 but are subject to
primary tissue failure and may therefore require rereplacement.6,7
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CDFactors like advanced age, left ventricular (LV) dysfunc-
tion, and an acute presentation with structural valve failure
or infective endocarditis may make reoperations on the
aortic valve a challenging proposition. Scarring, distortion,
and calcification of the aortic annulus and root present
increased technical difficulties, which may require recon-
struction of the aortic root. However, because surgical re-
sults have improved over time, reoperations on the aortic
valve may no longer carry the same increase in risks as in
the past. We therefore evaluated our experience with aortic
valve surgery to determine whether redo aortic valve replace-
ment (AVR) or Bentall-after-AVR procedures are indepen-
dent predictors of perioperative mortality.
Methods
Data Source
From January 1990 through December 2002, 2673 patients under-
went AVR with or without concomitant coronary artery bypass
grafting (CABG) at our institution. Of these, 2375 patients under-
went primary (first-time) AVR, and 298 patients (11.1%) under-
went redo aortic valve surgery. Clinical, operative, and outcome
data were collected prospectively in a computerized database on
all patients undergoing cardiac surgery. Patients who underwent
operations on other valves, ventricular aneurysm resection, ar-
rhythmia surgery, or extracardiac procedures were excluded from
this study.
Outcome and Explanatory Variables
Our primary outcome in this study was hospital mortality, which
was defined as any postoperative death in the hospital. We also
recorded age, sex, LV grade (based on left ventricular ejection
fraction [LVEF] obtained by means of ventriculography or echo-
cardiography as follows: grade 1, LVEF 60%; grade 2, LVEF
40%-59%; grade 3, LVEF 20%-39%; grade 4, LVEF 20%),
previous AVR, urgency of operation (elective; semiurgent, indi-
cating an operation during the same admission as a cardiac cath-
eterization or a cardiac event; urgent, indicating an operation
within 72 hours of an event; or emergency, indicating an operation
within 12 hours of an event), New York Heart Association
(NYHA) class, native and prosthetic aortic valve lesion (stenotic,
regurgitant, or mixed, as determined by means of echocardiogra-
phy) and infective endocarditis (active endocarditis, active endo-
carditis with abscess formation, remote endocarditis, or none),
recent (within 30 days) myocardial infarction, congestive heart
failure, diabetes, hyperlipidemia, peripheral vascular disease, hy-
Abbreviations and Acronyms
AVR  aortic valve replacement
CABG coronary artery bypass grafting
CI  confidence interval
LV  left ventricular
LVEF  left ventricular ejection fraction
NYHA New York Heart Associationpertension, and preoperative stroke or transient ischemic attack.
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Statistical analyses were performed with SAS (Version 8.2) soft-
ware.8 Univariate analyses were performed with 2 analyses or the
Fisher exact test for categoric variables and analysis of variance
for continuous variables. Variables that had a univariate P value of
less than .25 or those judged to be clinically important were
submitted to a logistic regression model by means of stepwise
selection. Multivariate logistic regression methods, validated by
means of bootstrap methodology, were used to calculate factor-
adjusted odds ratios. Model discrimination was evaluated by using
the area under the receiver operating characteristic curve,9,10 and
calibration was assessed with the Hosmer-Lemeshow goodness-
of-fit statistic.
Results
Demographics
Two thousand three hundred seventy-five (88.9%) patients
underwent first-time AVR (primary AVR), 216 (8.1%) pa-
tients underwent an aortic valve rereplacement (redo AVR),
and 82 (3.1%) patients underwent a modified Bentall proce-
dure or complete aortic root replacement with reimplantation
of coronary buttons after a previous AVR (Bentall-after-
AVR, Table 1). For patients in the redo AVR group, the
median duration between operations was 10.3 years (mean,
10.6  5.4 years). For patients in the Bentall-after-AVR
group, the median duration was 11.2 years (mean, 11.0 
6.2 years).
Patients undergoing reoperations were younger than
those undergoing primary AVR (P  .0001, Table E1).
Patients in the primary AVR group had predominantly aortic
stenosis, whereas patients in the redo AVR and Bentall-after-
AVR groups had predominantly aortic regurgitation (P 
.0001). Infective endocarditis and the need for urgent or
emergency operation were more common in the redo AVR
and Bentall-after-AVR groups (P  .0001).
Valvular Pathology
Eighty-three percent of patients in the redo AVR group and
71% in the Bentall-after-AVR group had received a bio-
prosthetic valve during their previous operation. Most ex-
planted bioprostheses demonstrated cusp tears, calcification,
and/or fusion, with many showing pannus ingrowth (Figure
1). Seventeen percent of patients in the redo AVR group and
29% in the Bentall-after-AVR group had received a me-
chanical valve during their previous operation. Most pa-
TABLE 1. Number of previous aortic valve operations in
patients undergoing redo operations
No. of operations Redo AVR (n) Bentall-after-AVR (n)
Second operation 191 70
Third operation 23 9
Fourth operation 2 3
Fifth operation 0 1
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CDtients in the redo AVR group had significant pannus in-
growth, whereas patients undergoing Bentall-after-AVR
procedures chiefly had paravalvular leaks or dehiscences
(Figure 2). One valve in the redo AVR group and 11 in the
Bentall-after-AVR group were found to be normal at patho-
logic review. These patients required reoperation predomi-
nantly because of abnormalities of the aortic root or prox-
imal ascending aorta.
Of the 82 patients in the Bentall-after-AVR group, the
indication for a root replacement was a type A acute or
chronic dissection in 10% of patients, dilation of the aortic
root in 20%, ascending aortic aneurysm in 12%, periannular
abscess in 18%, partial or complete excision of the annulus
during excision of the prosthesis in 16%, and a calcified,
friable, or abnormal aortic root in 20%. Seven patients
undergoing Bentall-after-AVR procedures had a Dacron or
pericardial patch enlargement or reconstruction of the aortic
root at the time of the previous operation.
Sixteen patients who had undergone primary AVR with
Toronto SPV bioprostheses required a reoperation. Eight
underwent a redo AVR, and 8 underwent a modified Bentall
or root replacement procedure. Eight patients who had un-
dergone primary AVR with a homograft required a reop-
eration. One patient underwent a redo AVR, and 7 under-
went a modified Bentall or root replacement procedure.
There were 2 more patients (one with a previous Medtronic
Freestyle valve in situ and the other who had undergone a
Ross procedure) who underwent redo AVR. Other com-
monly explanted tissue valves were Carpentier Edwards
Figure 1. Pathology of explanted bioprosthetic valves. AVR,
Aortic valve replacement.Porcine, Ionescu-Shiley, and Hancock II Porcine valves
The Journal of Thoraci(24%, 21%, and 20% of all tissue valves explanted, re-
spectively).
Intraoperative Data
The proportion of patients who received mechanical valves
was significantly higher in the redo AVR and Bentall-after-
AVR groups than in the primary AVR group (P  0.0001,
Table 2). A greater percentage of patients in the redo AVR
group required enlargement of the aortic annulus or one of
the sinuses (P  .05). Aortic crossclamp and cardiopulmo-
nary bypass times were longer in patients in the Bentall-
after-AVR group (P  .0001).
Outcomes
Hospital mortality was 2.3% for primary AVR, 4.6% for
redo AVR, and 2.4% for Bentall-after-AVR (Table 3). In
the redo AVR group, mortality was 3.7% for second oper-
ations, 13% for third operations, and 0% for fourth opera-
tions. In the Bentall-after-AVR group mortality was 2.9%
for second operations and 0% for third, fourth, or fifth
operations.
Univariate analyses showed that mortality was high in
patients undergoing emergency primary or redo AVR (Ta-
ble E2). Preoperative cardiogenic shock and congestive
heart failure increased mortality to a greater degree for redo
AVR than for primary AVR. In all groups the presence of
diabetes or active endocarditis or the requirement for patch
enlargement of the aortic root were associated with in-
creased mortality. Peripheral vascular disease and preoper-
ative renal failure increased mortality for primary or redo
Figure 2. Pathology of explanted mechanical valves. AVR, Aortic
valve replacement.AVR but not for Bentall-after-AVR.
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CDPostoperative low cardiac output syndrome, myocardial
infarction, or stroke did not differ between groups (Table 3),
but postoperative renal failure was more common after
reoperations (P  .04), as were re-exploration for bleeding
(P  .0001) and permanent pacemaker insertion (P  .02).
The durations of intensive care unit and hospital stay were
longer in patients undergoing reoperations (P  .02).
Predictors of Hospital Mortality for Aortic Valve
Operations and Reoperations
The independent predictors of mortality were determined by
multivariable logistic regression analysis (Figure 3) and
included increasing NYHA class (odds ratio, 2.3; 95%
confidence interval [CI], 1.5-3.4), infective endocarditis
(odds ratio, 2.9; 95% CI, 1.4-5.9), peripheral vascular dis-
ease (odds ratio, 3.6; 95% CI, 1.9-6.8), and the requirement
for aortic root enlargement (odds ratio, 2.1; 95% CI, 1.2-
3.7). However, reoperative aortic valve surgery was not a
significant predictor of hospital mortality.
When reoperation was forced into the model, its odds
ratio (odds ratio, 1.4; 95% CI, 0.7-2.9) was considerably
lower than those associated with NYHA class, endocarditis,
peripheral vascular disease, and root enlargement (P .34).
TABLE 2. Distribution of intraoperative variables
Variable Primary AVR
Valve type (%)
Mechanical 24
Bioprostheses 76
Prosthesis size (diameter in mm) 24 2.3
Annular enlargement (%)
Annulus 11
Sinuses 3.4
Both 5.4
Total 20
Duration of CPB (min) 110 37
Duration of XCL (min) 85 29
AVR, Aortic valve replacement; CPB, cardiopulmonary bypass; XCL, aortic
TABLE 3. Distribution of postoperative outcomes
Variable Primary AVR
Mortality (%) 2.3
Low output syndrome (%) 5.7
Postoperative MI (%) 1.6
Postoperative stroke (%) 2.4
Postoperative renal failure (%) 2.1
Pacemaker insertion (%) 5.6
Reopening for bleeding (%) 4.3
Duration of ventilation (h) 19 41
Duration of ICU stay (h) 54 71
Postoperative hospital stay (d) 10 7.4AVR, Aortic valve replacement; MI, myocardial infarction; ICU, intensive care u
332 The Journal of Thoracic and Cardiovascular Surgery ● FebrThe multivariable model for mortality was robust,
with an area under the receiver operating characteristic
curve of 0.735 and a Hosmer-Lemeshow goodness-of-fit
P value of .7, indicating good model calibration and
discrimination. We further validated the model with
bootstrap methodology (Table 4). The logistic regression
analysis was repeated 100 times in subsets of 2000 pa-
tients randomly selected from the entire dataset for each
analysis, with replacement. There was excellent correla-
tion of the predictors selected in the 100 bootstrap anal-
yses with those identified in the original model. As Table
4 indicates, NYHA class was identified as a significant
predictor of mortality in 98% of these multivariable
models and peripheral vascular disease in 96%, but only
4% of models identified reoperation as a predictor. The
finding that reoperation was not a significant predictor of
hospital mortality was therefore robust.
Discussion
Reoperative valvular surgery is often performed in higher-
risk patients rather than those undergoing primary proce-
dures and is more technically demanding. Reoperative aor-
Redo AVR Bentall-after-AVR P value
52 61 .0001
48 39
24 2.2 26  2 .0001
19 6.3 .0001
3.9 0
13 0
36 6.3
112 45 152  60 .0001
83 33 117 42 .0001
sclamp.
Redo AVR Bentall-after-AVR P value
4.6 2.4 .1
4.6 7.3 .7
0.9 0 .4
4.6 2.4 .1
4.2 4.9 .04
14 26 .0001
6.9 9.8 .02
25 52 26  77 .1
61 63 74  106 .02
11 8.1 12 9.4 .02nit.
uary 2006
Davierwala et al Surgery for Acquired Cardiovascular Disease
A
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1 or CABG11 has
therefore been associated with increased morbidity and
mortality compared with that seen with primary procedures.
Although some series have reported that prior CABG is not
a significant risk factor for mortality during subsequent
AVR,12,13 the incremental risk of aortic valvular reoperation
caused specifically by prior aortic valve surgery has been
difficult to quantify.
The desire to avoid subsequent high-risk reoperations
may encourage the implantation of mechanical valves be-
cause late freedom from structural failure is excellent.2
TABLE 4. Bootstrap analysis for validation of the multivar
Variable % of models
NYHA class 98
Peripheral vascular disease 96
Infective endocarditis 75
Aortic annular enlargement 61
Age 16
Preoperative MI 16
Cardiogenic shock 16
Diabetes 12
Congestive heart failure 10
Syncope-TIA 9
Preoperative renal failure 7
Redo vs primary AVR 4
Angina 1
Hyperlipidemia 0
Sex 0
Preoperative stroke 0
Figure 3. Independent predictors of hospital mortality
New York Heart Association.NYHA, New York Heart Association; MI, myocardial infarction; TIA, transient is
The Journal of ThoraciHowever, mechanical valves are subject to endocarditis and
paravalvular leaks, similar to bioprostheses, and valve
thrombosis and pannus ingrowth are not infrequent causes
for reoperation. Primary tissue failure is therefore the only
indication for reoperation that is specific to bioprosthe-
ses. The risk of reoperation for bioprosthetic tissue fail-
ure varies by patient age, with excellent valve durability
in patients aged 65 years or older.6,7,14-16 The likelihood
of reoperation for bioprosthetic failure may also be re-
duced by coronary artery disease, which represents a
competing risk.14 Bioprosthetic aortic valves typically
regression model
Parameter Standard error Odds ratio
0.7903631 0.0124215 2.2
1.2879542 0.0194414 3.6
1.2537879 0.0239282 3.5
0.8360244 0.0138950 2.3
0.0360655 0.0010653 —
1.2122562 0.0168738 —
1.3625971 0.0568888 —
0.8160644 0.0168738 —
0.9471899 0.0373594 —
1.3107508 0.0769650 —
1.3496172 0.0372488 —
0.9060861 0.0327348 —
0.7874441 — —
— — —
— — —
— — —
rimary or redo aortic valve replacement. NYHA,iatefor pchemic attack; AVR, aortic valve replacement.
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CDfail gradually, with an increasing incidence of reopera-
tion beginning after 7 to 8 years. In our series we noted
median intervals of 10.3 years between operations in the
redo AVR group and 11.2 years in the Bentall-after-AVR
group, which are very similar to those reported by Vogt
and colleagues.17
When aortic valvular rereplacement was carried out elec-
tively, mortality in our series was low (1.6% for elective
primary AVR vs 1.7% for elective redo AVR). Vogt and
colleagues17 noted a similarly low risk (1.4%) of elective
rereplacement of degenerated aortic bioprostheses, and
Akins and associates18 reported a 4.8% mortality in similar
patients. Jamieson and coworkers19 reported an overall mor-
tality of 6.8% in 322 reoperations for failed aortic bio-
prostheses.
In the current series reoperative surgery was associated
with a nonsignificantly increased risk of mortality (4.6% vs
2.3%). This difference may be due to the increased preva-
lence of other risk factors in patients undergoing reopera-
tions. For instance, patients presenting with active endocar-
ditis underwent urgent or emergency operations more often
in the redo AVR (10.8%) and Bentall-after-AVR (9.1%)
groups than in the group undergoing primary AVR (6.4%).
Timing of the operation is important because nonelective
operation was also reported to be a predictor of death by
Akins and associates,18 with an odds ratio of 2.5.
We also found that worsening NYHA class was a sig-
nificant predictor of hospital mortality, as did Jamieson and
coworkers.19 Reoperations may therefore involve greater
risk not just because of increased technical difficulties but
also because such patients often present urgently with en-
docarditis, congestive heart failure, or shock or with renal
failure related to sepsis. These conclusions were also
reached by Potter and colleagues,20 who recently analyzed
their institutional experience with reoperative aortic valve
surgery and concluded that mortality was related to endo-
carditis, advanced NYHA symptom class, peripheral vascu-
lar disease, preserved LV function, and male sex but not to
reoperation itself.
In this series an aggressive institutional practice of an-
nular enlargement was reflected in a prevalence of annular
enlargement of 20% in patients undergoing primary opera-
tions, 36% in patients undergoing redo AVR, and 6% in
patients undergoing Bentall procedures after prior AVR.
The nominal mean size of valve implanted at reoperation
was identical in patients undergoing primary AVR versus
redo AVR, whereas those undergoing Bentall procedures
received valves with larger sizes. It is likely that without the
greater prevalence of annular enlargement during redo
AVR, the mean size of prostheses reimplanted would have
been significantly lower. The requirement for annular en-
largement was associated, however, with a significant in-
crease in hospital mortality. Whether an increased operative
334 The Journal of Thoracic and Cardiovascular Surgery ● Febrrisk caused by annular enlargement is counterbalanced by
improved late survival related to a larger prosthesis and
improved hemodynamics remains controversial and cannot
be addressed by our current study.
Of the 298 patients who underwent reoperations, 82
patients required a Bentall procedure or aortic root replace-
ment for acute or chronic aortic dissections, aneurysmal
disease of the aortic root or ascending aorta, annular or
subannular abscess cavities, excision of the annulus with the
prosthesis, or a calcified or friable aortic root. Patients in
this group were younger but had a higher prevalence of
active and remote endocarditis and thus required more
emergency procedures. Despite this, the overall hospital
mortality for this group of patients was only 2.4%, which
compares favorably with the 11.5% mortality reported by
Vallely and associates21 for elective root replacement after
previous AVR and the 8.3% mortality noted by Dougenis
and coworkers22 for root replacement after prior AVR or
CABG. We attribute the low mortality in this series to a
number of factors, including concentration of cases to a
small number of experienced surgeons, ensuring safe sternal
reentry, careful myocardial protection, aggressive debride-
ment of all suspicious infected tissues, and reconstruction of
the heart with pericardium in patients with aortic root
abscesses.23
Because aortic bioprostheses do not require anticoagula-
tion with warfarin, they are indicated in young patients
whose physical activity increases the risk of anticoagulant-
related hemorrhage, women who wish to bear children,24
and those in whom anticoagulation cannot be safely moni-
tored and maintained. They are also indicated in elderly
patients undergoing AVR (65 years of age) because of
excellent durability and limited patient life expectancy. In
addition, some middle-aged patients (40-65 years) choose
bioprosthetic valves because of the desire to avoid warfarin
therapy. Our results suggest that the median interval be-
tween operations and the time course over which symptoms
of bioprosthetic tissue failure develop might support this
approach in carefully selected patients. When reoperation to
replace a failing tissue valve can be carried out on an
elective basis, the associated mortality is low.
The strategy of increased use of bioprosthetic valves
must be tempered by other mitigating factors. Patients who
already have another indication for lifelong warfarin anti-
coagulation usually have a mechanical valve implanted. In
addition, in patients with a small annulus at the time of the
initial operation, the necessity of an annular enlargement
procedure at future reoperation might be anticipated to be
greater, thereby increasing the mortality of reoperation. A
mechanical prosthesis, stentless bioprosthesis, or composite
root replacement may be better choices for such patients.
However, reoperations in patients who have undergone pre-
vious stentless valve implantation or root replacement may
uary 2006
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CDbe technically more complex. Because patients who under-
went aortic root replacement at their initial operation were
not included in this series, we are unable to comment on
mortality at reoperation in this more challenging patient
subgroup.
In conclusion, our experience suggests that the mortality
of AVR is strongly related to peripheral vascular disease,
endocarditis, NYHA symptom class, and the requirement
for annular enlargement. Reoperation itself is not signifi-
cantly associated with mortality. Bioprostheses implanted to
avoid anticoagulation can often be replaced electively with
low mortality. Although bioprostheses are not indicated in
all patients, the anticipated risk of reoperation may be a less
significant consideration in preoperative valve selection in
the future.
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CDTABLE E1. Distribution of preoperative variables
Variable Primary AVR Redo AVR Bentall-after-AVR P value
No. of patients (n) 2375 216 82
Age (y) 65 13 59 14 56  15 .0001
Sex (%)
Male 67 72 79 .02
Female 33 28 21
NYHA class (%)
I 4.4 5.1 15 .0001
II 23 17 23
III 46 44 24
IV 26 33 38
Diabetes mellitus (%) 16 8.8 11
Hypertension (%) 44 41 40
Hyperlipidemia (%) 31 20 22
Aortic valve prosthesis lesion (%)
Stenosis 67 13 5.3 .0001
Regurgitation 14 60 64
Mixed 19 26 25
Infective endocarditis (%)
Active 1.9 3.3 1.2 .0001
Active, with abscess 0.5 4.2 8.5
Remote 1.6 9.9 17
Preoperative cardiogenic shock (%) 3.1 1.4 0 .1
Congestive heart failure (%) 52 73 43 .0001
Preoperative syncope (%) 20 7.9 2.4 .0001
Left ventricular ejection fraction (%)
60 43 32 23 .0009
40-59 40 48 59
20-39 15 17 17
20 2.2 3.2 1.2
Preoperative stroke (%) 10 18 15 .002
Peripheral vascular disease (%) 8.5 6 2.4 .07
CABG (%) 46 31 29 .0001
Urgency of operation (%)
Elective 69 54 49 .0001
Same hospitalization 24 30 27
Urgent 6.2 13 17
Emergency 1.1 2.8 7.3
AVR, Aortic valve replacement; NYHA, New York Heart Association; CABG, coronary artery bypass grafting.335.e1 The Journal of Thoracic and Cardiovascular Surgery ● February 2006
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CDTABLE E2. Influence of preoperative and intraoperative variables on hospital mortality by univariate analysis
Variable Primary AVR Redo AVR Bentall-after-AVR
No. of procedures (%)
1 2.3 (54/2375) NA NA
2 NA 3.7 (7/
191)
2.9 (2/70)
3 NA 13 (3/23) 0 (0/9)
4 NA 0 (0/2) 0 (0/3)
Urgency of operation (%)
Elective 1.6 1.7 2.5
Same hospitalization 3.2 9.2 0
Urgent 2.7 3.6 7.1
Emergency 22 17 0
P value .0001 .06 .6
Preoperative cardiogenic shock (%)
Yes 8.2 33 NA
No 2.1 4.2
P value .0005 .02
Congestive heart failure (%)
Yes 3.2 6.4 2.9
No 1.2 0 2.1
P value .001 .04 .8
Infective endocarditis (%)
None or remote 2.1 3.4 0
Active or active with abscess 6.4 11 9.1
P value .07 .05 .02
Left ventricular ejection fraction (%)
60 1.9 4.4 0
40-59 1.9 4.9 2.1
20-39 4.3 5.4 7.1
20 1.9 0 0
P value .05 .9 .6
Diabetes
Yes 4.5 5.3 11
No 1.9 4.6 1.4
P value .002 .9 .07
Peripheral vascular disease (%)
Yes 6.4 23 0
No 1.9 3.5 2.5
P value .0001 .001 .8
Preoperative renal failure (%)
Yes 6.1 22 0
No 2.2 3.9 2.6
P value .06 .01
Aortic root enlargement (%)
Yes 3.5 11 20
No 1.9 1.5 1.3
P value .03 .003 .01AVR, Aortic valve replacement; NA, not applicable.
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